Paratek Pharmaceuticals (NASDAQ:PRTK) has climbed 6.06% in the past week and advanced 20.43% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 7.33% and the outperformance has advanced to 19.33% for the last 4 weeks period.
Paratek Pharmaceuticals (NASDAQ:PRTK): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $18.41 and $16.82 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $18.92. The buying momentum continued till the end and the stock did not give up its gains. It closed at $16.98, notching a gain of 3.28% for the day. The total traded volume was 1,790,696 . The stock had closed at $16.44 on the previous day.
The company shares have dropped -37.32% from its 1 Year high price. On Jun 23, 2015, the shares registered one year high at $29.83 and the one year low was seen on Feb 9, 2016. The 50-Day Moving Average price is $14.81 and the 200 Day Moving Average price is recorded at $15.57.
On the companys insider trading activities, Loh Evan, director officer (President and CMO) of Paratek Pharmaceuticals, Inc. had purchased 2,300 shares on December 10, 2015 in a transaction. The price per share was $16.83 and the total amount of the disclosed transaction was $38,709.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.
Many analysts have stated their opinion on the company shares. Equity analysts at the Brokerage firm Ladenburg Thalmann maintains its rating on Paratek Pharmaceuticals (NASDAQ:PRTK). The rating major has initiated the coverage with buy rating on the shares. The Analysts at Ladenburg Thalmann raises the price target from $46 per share to $52 per share. The rating by the firm was issued on June 17, 2016. Currently the company Insiders own 2% of Paratek Pharmaceuticals shares according to the proxy statements. Institutional Investors own 79.44% of Paratek Pharmaceuticals shares.
Paratek Pharmaceuticals, Inc. (Paratek), formerly Transcept Pharmaceuticals, Inc. is a pharmaceutical company focused on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry. Parateks two antibacterial product candidates are omadacycline and sarecycline. Omadacycline is a broad-spectrum antibiotic for use as an empiric monotherapy for community-acquired bacterial infections, such as acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP) and urinary tract infections (UTI). Sarecycline is in Phase III clinical trial stage for the treatment of acne, and omadacycline has completed Phase III clinical trial for treatment of complicated skin and skin structure infection (cSSSI), and Phase II clinical trials for the treatment of ABSSSI and CABP. Sarecycline is a once-daily, tetracycline-derived compound designed for use in the treatment of acne and rosacea.